Showing results (1281-1290 of 1,614) with videos related to

Sort By:
Pageof 162
RSC Medicinal Chemistry|May 15, 2025
Macrocyclic RGD-peptides with high selectivity for αvβ3 integrin in cancer imaging and therapyXiaozhong Cheng, Chen Li, Haofei Hong, et al.
RSC Medicinal Chemistry|May 21, 2025
Photoresponsive prodrug for regulated inhibition of indoleamine 2,3-dioxygenase 1 enzyme activityNiku Moni Das, Biswa Mohan Prusty, Adyasa Sahoo, et al.
RSC Medicinal Chemistry|May 8, 2025
Discovery of novel antimyeloma agents targeting TRIP13 by molecular modeling and bioassaySamuel Jacob Bunu, Haiyan Cai, Zhaoyin Zhou, et al.
RSC Medicinal Chemistry|May 2, 2025
Human chitinases and chitinase-like proteins as emerging drug targets - a medicinal chemistry perspectiveÖnder Kurç, Nick Rähse, Holger Gohlke, et al.
RSC Medicinal Chemistry|April 25, 2025
VHL-independent degradation of hepatitis B virus e antigen (HBeAg) by VHL-binding chimeric small moleculesLiam T Hales, Simon J Mountford, Mina Takawy, et al.
RSC Medicinal Chemistry|March 26, 2025
Contributors to our Emerging Investigators collection
RSC Medicinal Chemistry|November 17, 2025
Design, synthesis, and biological evaluation of procaine-based triazole-isoxazoline hybrids as selective PI3K/mTOR inhibitors for esophageal cancer therapy: in vitro and in vivo studiesYinliang Sheng, Bin Wu, Feng Li, et al.
RSC Medicinal Chemistry|November 14, 2025
Investigating NFE2L1 activators for targeted protein aggregate clearance: a follow-up studyZuzana Smahelova, Lucie Svobodova, Jindrich Sedlacek, et al.
RSC Medicinal Chemistry|September 24, 2025
The rise of ultrashort cationic β-peptides as promising antimicrobial therapeuticsHadiya Amin Kantroo, Itibaw Farooq, Zahoor Ahmad
RSC Medicinal Chemistry|August 18, 2025
CDK2 inhibitors: rationally directed discovery of a novel potent lead derived from cyclohepta[e]thieno[2,3-b]pyridineOmaima F Ibrahim, Raed M Maklad, Hajjaj H M Abdu-Allah, et al.
Pageof 162